ABSTRACT
No disponible
Subject(s)
Humans , Male , Adult , Venous Thromboembolism/etiology , Cocaine-Related Disorders/complications , Venous Thromboembolism/diagnostic imaging , Leukocytosis/complications , Venae Cavae/diagnostic imaging , Venae Cavae/pathology , Positron Emission Tomography Computed TomographyABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Brain Diseases/diagnostic imaging , Brain Diseases/drug therapy , Porphyrias/complications , Brain Diseases/physiopathology , Migraine Disorders , Psoriasis , Abdominal Pain/etiologyABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Pyomyositis/etiology , Pyomyositis/therapy , Thrombophlebitis/complications , Leukocytosis/complications , Thrombophlebitis/diagnostic imaging , Thrombophlebitis/drug therapy , Lower Extremity/diagnostic imaging , Lower Extremity/pathology , Adrenal Cortex Hormones/therapeutic useSubject(s)
Porphyria, Acute Intermittent/complications , Posterior Leukoencephalopathy Syndrome/etiology , Adult , Antihypertensive Agents/therapeutic use , Female , Humans , Labetalol/therapeutic use , Magnetic Resonance Imaging , Porphyria, Acute Intermittent/diagnosis , Posterior Leukoencephalopathy Syndrome/diagnosis , Posterior Leukoencephalopathy Syndrome/drug therapySubject(s)
Pyomyositis/etiology , Thrombophlebitis/complications , Adrenal Cortex Hormones/therapeutic use , Female , Humans , Middle Aged , Postoperative Complications/drug therapy , Postoperative Complications/etiology , Pyomyositis/diagnostic imaging , Staphylococcal Infections/complications , Staphylococcus aureusABSTRACT
BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent mast cell-driven disease that affects approximately 0.5-1% of the population. Antihistamines are currently the drugs of choice in patients with CSU. Omalizumab has been shown to be very effective in CSU and has been recently approved as second-line therapy. However, although its introduction has markedly improved the therapeutic possibilities for CSU, there is still a hard core of patients who do not respond and require effective treatment. METHODS: We report the case of a patient who achieved an 8-month remission of refractory CSU following the use of rituximab, and perform a review of the literature regarding the use of rituximab in CSU. RESULTS: There was a remarkable improvement in her CSU after the administration of rituximab maintained over time. CONCLUSION: Rituximab is a chimeric murine/human monoclonal antibody directed against CD20, which depletes memory B-lymphocytes that are necessary for autoantibody production. The abrogation of the autoantibody production is the proposed mechanism by which it may alleviate the symptoms of CSU.